TRANSTEC® 35 micrograms/h Transdermal Patch
*Company:
Grunenthal Pharma Ltd.Status:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 18 December 2024
File name
ie-pl-transtec-clean.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 3 - how to take/use
- Change to section 5 - how to store or dispose
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
HPRA approval to update the product information (SmPC and PIL) for all the Transtec products following buprenorphine PSUSA outcome EMEA/H/C/PSUSA/00000459/202309.
Updated on 18 December 2024
File name
ie-spc-transtec-35-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
HPRA approval to update the product information (SmPC and PIL) for all the Transtec products following buprenorphine PSUSA outcome EMEA/H/C/PSUSA/00000459/202309.
Updated on 22 May 2023
File name
ie-spc-transtec-35-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 22 May 2023
File name
ie-pl-transtec-clean.pdf
Reasons for updating
- New PIL for new product